Talzenna (talazoparib) vs Tukysa (tucatinib)
Talzenna (talazoparib) vs Tukysa (tucatinib)
Talzenna (talazoparib) is a PARP inhibitor used primarily to treat certain types of breast cancer in patients who have inherited BRCA mutations. Tukysa (tucatinib), on the other hand, is a tyrosine kinase inhibitor that is used in combination with other drugs to treat HER2-positive breast cancer, which is a different subtype of breast cancer characterized by the overexpression of the HER2 protein. The choice between Talzenna and Tukysa would largely depend on the patient's specific breast cancer characteristics and genetic markers, as well as the overall treatment plan determined by their oncologist.
Difference between Talzenna and Tukysa
Metric | Talzenna (talazoparib) | Tukysa (tucatinib) |
---|---|---|
Generic name | talazoparib | tucatinib |
Indications | HER2-negative breast cancer with germline BRCA mutations | HER2-positive breast cancer |
Mechanism of action | Poly (ADP-ribose) polymerase (PARP) inhibitor | HER2 tyrosine kinase inhibitor |
Brand names | Talzenna | Tukysa |
Administrative route | Oral | Oral |
Side effects | Anemia, neutropenia, thrombocytopenia, fatigue, nausea, headache | Diarrhea, palmar-plantar erythrodysesthesia, nausea, fatigue, hepatotoxicity |
Contraindications | Known hypersensitivity to talazoparib | Known hypersensitivity to tucatinib |
Drug class | Poly (ADP-ribose) polymerase (PARP) inhibitor | Tyrosine kinase inhibitor |
Manufacturer | Pfizer | Seagen Inc. |
Efficacy
Talzenna (Talazoparib) Efficacy in Breast Cancer
Talzenna (talazoparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor that has been approved for use in certain patients with breast cancer. Specifically, it is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. Patients are selected for therapy based on an FDA-approved companion diagnostic for Talzenna. The efficacy of Talzenna was demonstrated in the EMBRACA trial, a phase 3 study where patients treated with Talzenna showed a significant improvement in progression-free survival (PFS) compared to those who received standard chemotherapy. Patients receiving Talzenna had a median PFS of 8.6 months versus 5.6 months in the chemotherapy group.
Tukysa (Tucatinib) Efficacy in Breast Cancer
Tukysa (tucatinib) is an oral tyrosine kinase inhibitor that is used in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. The approval of Tukysa was based on the results of the HER2CLIMB trial, a randomized, double-blind, placebo-controlled, multicenter study. The trial demonstrated that patients who received Tukysa in combination with trastuzumab and capecitabine had a significant improvement in progression-free survival as well as overall survival. The median PFS was 7.8 months for patients in the Tukysa arm compared to 5.6 months for those in the control arm.
Both Talzenna and Tukysa represent important advancements in the treatment of breast cancer, offering new hope for patients with specific genetic and molecular profiles of the disease. These targeted therapies underscore the importance of personalized medicine in oncology, where treatments can be tailored to the individual characteristics of a patient's cancer. As with any medication, the efficacy of Talzenna and Tukysa can vary among individuals, and their use should be based on a comprehensive evaluation of the patient's health status and the presence of biomarkers that predict a favorable response to these drugs.
It is important for healthcare providers to stay informed about the latest clinical data and treatment guidelines to ensure that patients with breast cancer receive the most effective and appropriate therapy. Ongoing research and clinical trials continue to refine the use of these medications and expand our understanding of their role in the management of breast cancer.
Regulatory Agency Approvals
Talzenna
Tukysa
Access Talzenna or Tukysa today
If Talzenna or Tukysa are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us